UNIVERSITE PARIS DIDEROT - PARIS 7
Patent Owner
Stats
- 42 US PATENTS IN FORCE
- 27 US APPLICATIONS PENDING
- Mar 01, 2018 most recent publication
Details
- 42 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 391 Total Citation Count
- May 18, 2006 Earliest Filing
- 26 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0045,729 MUTANT SMOOTHENED AND METHODS OF USING THE SAMEFeb 04, 16Feb 15, 18[A61K, C12Q, G01N, C07K]
2018/0021,302 PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUSFeb 12, 16Jan 25, 18[A61K]
2018/0022,781 POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPYFeb 12, 16Jan 25, 18[C12N, C07K]
2018/0023,204 SELECTIVE PORPHYRIN-CATALYZED ELECTROCHEMICAL REDUCTION OF CO2 INTO CO IN WATERFeb 02, 16Jan 25, 18[C25B, C07F]
2017/0362,302 Method and Pharmaceutical Composition for Use in the Treatment of CancerAug 28, 17Dec 21, 17[A61K, C07K]
2017/0319,661 Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate CancersDec 03, 14Nov 09, 17[A61K, C12N, G01N, C07K]
2017/0313,758 Polypeptides for the Treatment of Angiogenesis or Lymphangiogenesis-Related DiseasesNov 24, 15Nov 02, 17[A61K, C12N, C07K]
2017/0216,417 POPULATION OF IMMUNOREGULATORY T CELLS SPECIFIC FOR AN IRRELEVANT ANTIGEN AND USES THEREOF FOR PREVENTING OR TREATING IMMUNE DISEASESFeb 07, 17Aug 03, 17[A61K, C12N]
2017/0209,488 METHODS FOR TREATING NEUROMUSCULAR JUNCTION-RELATED DISEASESJul 16, 15Jul 27, 17[A61K]
2017/0181,729 METHOD FOR OBTAINING A FUNCTIONAL PARAMETER OF A MUSCLEJul 17, 15Jun 29, 17[A61B, G01S]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9879325 Method for predicting the responsiveness a patient to a treatment with an anti-CD20 antibodyFeb 27, 15Jan 30, 18[A61K, C12Q, G01N, C07K]
9873877 Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyriaMar 24, 17Jan 23, 18[C12N]
9856526 Method for electrochemically identifying target nucleotide sequencesJan 15, 15Jan 02, 18[C12Q]
9757494 Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formationJun 02, 15Sep 12, 17[C08J, C08B, A61L]
9688742 Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)Sep 18, 14Jun 27, 17[A61K, A01N, C12N, C07K]
9637744 Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyriaJun 13, 14May 02, 17[C07H, C12N]
9629896 Composition including the HIP/PAP protein or one of the derivatives thereof for treating insulin resistanceApr 04, 14Apr 25, 17[A61K]
9594083 Method for the treatment of cardiovascular fibrosisSep 27, 13Mar 14, 17[A61K, C12N, G01N, C07K]
9555164 Method for preparing porous scaffold for tissue engineeringMay 11, 15Jan 31, 17[C08J, C08H, A61F, C12N, C08B, A61L]
9547006 Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planusAug 08, 14Jan 17, 17[A61K, C12Q, C12N, G01N, A61N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0000,849 CD300A RECEPTORS AS VIRUS ENTRY COFACTORSAbandonedDec 19, 14Jan 05, 17[A61K, C12N, C07K]
2016/0123,982 METHODS FOR ASSAYING JAK2 ACTIVITY IN RED BLOOD CELLS AND USES THEREOFAbandonedFeb 04, 14May 05, 16[G01N]
2015/0232,954 Method for quantifying different viral forms of the DNA of the HIV virusAbandonedJun 12, 13Aug 20, 15[C12Q]
2015/0218,242 TIF1-Gamma for Treating and Diagnosing Inflammatory DiseasesAbandonedJul 31, 13Aug 06, 15[C12Q, A01K, C07K]
2015/0197,574 USE OF TRANSFERRIN RECEPTOR ANTAGONIST FOR THE TREATMENT OF THALASSEMIAAbandonedAug 02, 13Jul 16, 15[C07K]
2015/0133,381 METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF FAMILIAL THORACIC AORTIC ANEURYSMS CAUSED BY TGFB2 LOSS OF FUNCTION MUTATIONSAbandonedMay 15, 13May 14, 15[A61K, C12Q]
2015/0011,560 ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3AbandonedDec 12, 12Jan 08, 15[A61K]
2015/0004,182 POPULATION OF IMMUNOREGULATORY T CELLS SPECIFIC FOR AN IRRELEVANT ANTIGEN AND USES THEREOF FOR PREVENTING OR TREATING IMMUNE DISEASESAbandonedNov 23, 12Jan 01, 15[A61K]
2015/0004,190 VACCINE COMPOSITIONS FOR HIV PREVENTION AND TREATMENTAbandonedJan 25, 13Jan 01, 15[A61K, C12N]
2013/0344,033 RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS)AbandonedMay 21, 13Dec 26, 13[C12N]
2013/0323,217 COMPOSITIONS AND METHODS FOR THE CONTROLLED REPOPULATION OF GRAM-NEGATIVE BACTERIA IN THE COLONAbandonedDec 22, 11Dec 05, 13[A61K]
2013/0224,277 POROUS POLYSACCHARIDE SCAFFOLD COMPRISING NANO-HYDROXYAPATITE AND USE FOR BONE FORMATIONAbandonedAug 30, 11Aug 29, 13[A61L]
2013/0149,295 FURIN AND BIOLOGICALLY ACTIVE DERIVATIVES THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASEAbandonedMay 12, 11Jun 13, 13[A61K, C12N]
2013/0053,336 TREATMENT OF CHLAMYDIACEAE INFECTIONS BY MEANS OF BETA-LACTAMSAbandonedJan 13, 11Feb 28, 13[A61K, A61P]
2012/0195,859 RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS)AbandonedJan 24, 12Aug 02, 12[A61K, C12N, A61P, C07K]
2012/0058,936 COMPOSITIONS AND METHODS FOR ELIMINATION OF GRAM NEGATIVE BACTERIAAbandonedMar 12, 10Mar 08, 12[A61K, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.